25
https://pubmed.ncbi.nlm.nih.gov/38114660
The study found that combining olaparib with ATR/CHK1 inhibitors enhances cytotoxic activity in olaparib-resistant ovarian cancer cells with BRCA2 reversion mutation, alters DNA damage response protein expression, and abrogates olaparib-induced upregulation of proteins determining cell fate after DNA damage.